CPT code 53852 denotes radiofrequency ablation of prostatic tissue for the treatment of benign prostatic hypertrophy (BPH). This code captures a minimally invasive surgical approach intended to reduce obstructive prostatic tissue and relieve lower urinary tract symptoms in male patients. Nationally, procedures coded with 53852 are relevant to urology practice patterns, outpatient surgical volumes, and payer coverage policies for newer minimally invasive BPH therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical indication for the code, typical sites of service, and common billing context. The publication summarizes benchmark payment and utilization considerations, highlights relevant policy and coverage updates affecting adoption of ablative therapies for BPH, and places the procedure in clinical context relative to other surgical and office-based BPH treatments.

This resource is intended for billing managers, practice administrators, and policy analysts seeking a clear statement of what CPT code 53852 represents, how it is typically delivered, and what national payers consider when assessing coverage and payment for radiofrequency ablation of the prostate.